Lippincott Williams & Wilkins



SUPPLEMENTAL DIGITAL CONTENTa Phase 2b, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study OF THE NEUROKININ 3 RECEPTOR ANTAGONIST FEZOLINETANT FOR VASOMOTOR SYMPTOMS associated with menopauseGraeme L. Fraser, PhD; Samuel Lederman, MD; Arthur Waldbaum, MD; Robin Kroll, MD; Nanette Santoro, MD; Misun Lee, PhD; Laurence Skillern, MD; Steven Ramael, MDCONTENTSTable S1. Secondary Efficacy Outcomes: Frequency of Moderate/Severe VMS and Severity per 24 Hours in Weeks 1 and 2, Full Analysis SetTable S2. Secondary Efficacy Outcomes: Frequency of Mild/Moderate/Severe VMS and Severity per 24 Hours, Full Analysis SetTable S3. Liver Function Tests, Safety Analysis SetFigure S1. Response Rates and Odds of Response with Fezolinetant Versus Placebo Based on ≥50% Reduction in Frequency of Moderate/Severe VMS at Last On-Treatment Visit, Full Analysis SetFigure S2. Endometrial Thickness, Safety Analysis SetTable S1. Secondary Efficacy Outcomes: Frequency of Moderate/Severe VMS and Severity per 24 Hours in Weeks 1 and 2, Full Analysis SetWkTreatment group (n)Frequency of moderate/severe VMSper 24 hoursaSeverity of moderate/severe VMSper 24 hoursaChange from baselineDifference from placeboChange from baselineDifference from placeboMean (SE)Mean (SE)95% CIP valueMean (SE)Mean (SE)95% CIP value1Placebo (n=42)-2.1 (0.59)———-0.1 (0.10)———Fezolinetant15 mg BID (n=45)-3.8 (0.56)-1.7 (0.78)-3.23, -0.17.0297-0.4 (0.09)-0.3 (0.13)-0.60, -0.08.009830 mg BID (n=43)-5.3 (0.58)-3.1 (0.78)-4.66, -1.58<.0001-0.5 (0.10)-0.4 (0.13)-0.63, -0.11.004860 mg BID (n=43)-5.7 (0.57)-3.6 (0.78)-5.10, -2.02<.0001-0.6 (0.10)-0.5 (0.13)-0.80, -0.28<.000190 mg BID (n=41)-6.4 (0.60)-4.2 (0.79)-5.78, -2.66<.0001-0.8 (0.10)-0.7 (0.13)-1.00, -0.47<.000130 mg QD (n=41)-3.3 (0.60)-1.2 (0.79)-2.76, 0.36.1378-0.1 (0.10)-0.1 (0.13)-0.32, 0.21.676160 mg QD (n=44)-4.7 (0.56)-2.6 (0.78)-4.13, -1.05.0010-0.4 (0.09)-0.3 (0.13)-0.57, -0.05.0188120 mg QD (n=44)-4.7 (0.58)-2.6 (0.78)-4.10, -1.04.0011-0.4 (0.10)-0.4 (0.13)-0.61, -0.10.00672Placebo (n=42)-3.7 (0.60)———-0.2 (0.12)———Fezolinetant15 mg BID (n=44)-5.3 (0.57)-1.6 (0.79)-3.20, -0.07.0405-0.5 (0.12)-0.4 (0.17)-0.68, -0.03.033530 mg BID (n=42)-6.8 (0.59)-3.1 (0.80)-4.70, -1.55.0001-0.7 (0.12)-0.6 (0.17)-0.91, -0.25.000760 mg BID (n=43)-6.8 (0.58)-3.1 (0.80)-4.66, -1.52.0001-1.0 (0.12)-0.8 (0.17)-1.14, -0.48<.000190 mg BID (n=39)-7.3 (0.61)-3.7 (0.81)-5.26, -2.07<.0001-1.2 (0.13)-1.1 (0.17)-1.41, -0.74<.000130 mg QD (n=41)-5.4 (0.61)-1.7 (0.81)-3.34, -0.15.0325-0.3 (0.13)-0.2 (0.17)-0.50, 0.17.322760 mg QD (n=43)-6.0 (0.57)-2.4 (0.80)-3.92, -0.78.0035-0.6 (0.12)-0.4 (0.17)-0.77, -0.11.0085120 mg QD (n=43)-5.7 (0.59)-2.1 (0.79)-3.61, -0.49.0102-0.8 (0.12)-0.6 (0.17)-0.95, -0.30.0002aFrom mixed effect model for repeated measures, with change from baseline as the dependent variable and treatment group, visit, and smoking status as factors and baseline measurement as a covariate, as well as interaction of treatment by week and an interaction of baseline measurement by week.Table S2. Secondary Efficacy Outcomes: Frequency of Mild/Moderate/Severe VMS and Severity per 24 Hours, Full Analysis SetWkTreatment group (n)Frequency of mild/moderate/severe VMSper 24 hoursaSeverity of mild/moderate/severe VMSper 24 hoursaChange from baselineDifference from placeboChange from baselineDifference from placeboMean (SE)Mean (SE)95% CIP valueMean (SE)Mean (SE)95% CIP value4Placebo (n=42)-4.0 (0.63)———-0.3 (0.13)———Fezolinetant15 mg BID (n=40)-5.7 (0.60)-1.7 (0.84)-3.36, -0.06.0428-0.8 (0.12)-0.5 (0.18)-0.85, -0.16.004630 mg BID (n=41)-7.0 (0.62)-3.0 (0.84)-4.65, -1.34.0004-1.0 (0.13)-0.6 (0.18)-0.99, -0.29.000360 mg BID (n=40)-7.2 (0.61)-3.2 (0.84)-4.88, -1.58.0001-1.1 (0.13)-0.8 (0.18)-1.14, -0.45<.000190 mg BID (n=37)-8.1 (0.64)-4.1 (0.85)-5.73, -2.37<.0001-1.4 (0.13)-1.1 (0.18)-1.41, -0.70<.000130 mg QD (n=40)-6.0 (0.64)-2.0 (0.85)-3.64, -0.28.0225-0.8 (0.13) -0.4 (0.18)-0.77, -0.06.020960 mg QD (n=43)-6.8 (0.60)-2.8 (0.84)-4.49, -1.19.0008-0.9 (0.12)-0.6 (0.18)-0.93, -0.24.0011120 mg QD (n=42)-7.1 (0.62)-3.1 (0.84)-4.70, -1.42.0003-1.1 (0.13)-0.7 (0.18)-1.07, -0.38<.000112Placebo (n=37)-5.7 (0.58)———-0.8 (0.15)———Fezolinetant15 mg BID (n=38)-7.1 (0.54)-1.4 (0.76)-2.90, 0.09.0653-1.2 (0.15)-0.4 (0.21)-0.80, 0.02.059630 mg BID (n=37)-7.6 (0.57)-2.0 (0.76)-3.46, -0.47.0102-1.3 (0.15)-0.4 (0.21)-0.85, -0.03.036060 mg BID (n=31)-8.5 (0.57)-2.9 (0.77)-4.38, -1.36.0002-1.6 (0.15)-0.7 (0.21)-1.15, -0.32.000690 mg BID (n=31)-8.8 (0.59)-3.2 (0.78)-4.72, -1.67<.0001-1.6 (0.16)-0.8 (0.21)-1.23, -0.39.000230 mg QD (n=33)-7.4 (0.59)-1.8 (0.78)-3.30, -0.25.0231-1.0 (0.15)-0.2 (0.21)-0.62, 0.21.322760 mg QD (n=36)-8.0 (0.55)-2.4 (0.76)-3.88, -0.87.0021-1.3 (0.15)-0.5 (0.21)-0.89, -0.07.0220120 mg QD (n=36)-8.1 (0.57)-2.5 (0.76)-3.96, -0.97.0013-1.3 (0.15)-0.4 (0.21)-0.84, -0.02.0380aFrom mixed effect model for repeated measures with change from baseline as the dependent variable and treatment group, visit, smoking status as factors and baseline measurement as a covariate, as well as interaction of treatment by week and an interaction of baseline measurement by week.Table S3. Liver Function Tests, Safety Analysis SetParameterPlacebo (n=42)Fezolinetant, n (%)15 mg BID (n=43)30 mg BID (n=41)60 mg BID (n=41)90 mg BID (n=40)30 mg QD (n=41)60 mg QD (n=43)120 mg QD (n=42)AST or ALT, n (%)>3 × ULN001 (2.4)3 (7.3)2 (5.0)01 (2.3)2 (4.8)>5 × ULN0001 (2.4)2 (5.0)01 (2.3)1 (2.4)>8 × ULN0001 (2.4)1 (2.5)01 (2.3)0>10 × ULN0000001 (2.3)0Total bilirubin, n (%)>1.5 × ULN001 (2.4)0001 (2.3)0>2.0 × ULN00000000Alkaline phosphatase >1.5 × ULN, n (%)002 (4.9)1 (2.4)02 (4.9)2 (4.7)0ALT and/or AST >3 × ULN and total bilirubin 2 × ULN, n (%)00000000ALT and/or AST >3 × ULN and ALP <2 × ULN and total bilirubin >2 × ULN, n (%)00000000ALT=alanine aminotransferase; AST=aspartate aminotransferase; ULN=upper limit of normal.Figure S1. Response Rates and Odds of Response with Fezolinetant Versus Placebo Based on ≥50% Reduction in Frequency of Moderate/Severe VMS at Last On-Treatment Visit, Full Analysis SetVMS=vasomotor symptoms.aP<.05 for all pairwise comparisons of fezolinetant vs placebo, with no adjustments for multiplicity.Figure S2. Endometrial Thickness, Safety Analysis Set ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download